Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in Alcohol Use Disorder
NCT03904849Phase 2Withdrawn
- Sponsor
- Medical University of South Carolina
- Start
- Oct 2019
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Cannabidiol Arm with Placebo Arm (2 arms). Primary endpoints: Average alcohol-induced sedation after medication ingestion at 120 months and Average subjective response to alcohol after medication ingestion at 120 months. Planned start Oct 2019; status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03904849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904849.